These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 36333181)
21. PTEN loss confers sensitivity to rapalogs in clear cell renal cell carcinoma. Liu XL; Zhang GM; Huang SS; Shi WH; Ye LX; Ren ZL; Zhang JJ; Liu SW; Yu L; Li YL Acta Pharmacol Sin; 2022 Sep; 43(9):2397-2409. PubMed ID: 35165399 [TBL] [Abstract][Full Text] [Related]
22. Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype. Takenaka M; Köbel M; Garsed DW; Fereday S; Pandey A; Etemadmoghadam D; Hendley J; Kawabata A; Noguchi D; Yanaihara N; Takahashi H; Kiyokawa T; Ikegami M; Takano H; Isonishi S; Ochiai K; Traficante N; Gadipally S; Semple T; Vassiliadis D; Amarasinghe K; Li J; Mir Arnau G; Okamoto A; Friedlander M; Bowtell DDL; Clin Cancer Res; 2019 Jul; 25(13):3962-3973. PubMed ID: 30967419 [TBL] [Abstract][Full Text] [Related]
23. Precision medicine for ovarian clear cell carcinoma based on gene alterations. Kuroda T; Kohno T Int J Clin Oncol; 2020 Mar; 25(3):419-424. PubMed ID: 32020380 [TBL] [Abstract][Full Text] [Related]
24. DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. Cunningham JM; Winham SJ; Wang C; Weiglt B; Fu Z; Armasu SM; McCauley BM; Brand AH; Chiew YE; Elishaev E; Gourley C; Kennedy CJ; Laslavic A; Lester J; Piskorz A; Sekowska M; Brenton JD; Churchman M; DeFazio A; Drapkin R; Elias KM; Huntsman DG; Karlan BY; Köbel M; Konner J; Lawrenson K; Papaemmanuil E; Bolton KL; Modugno F; Goode EL Cancer Epidemiol Biomarkers Prev; 2022 Jan; 31(1):132-141. PubMed ID: 34697060 [TBL] [Abstract][Full Text] [Related]
25. Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management. Oda K; Hamanishi J; Matsuo K; Hasegawa K Gynecol Oncol; 2018 Nov; 151(2):381-389. PubMed ID: 30217369 [TBL] [Abstract][Full Text] [Related]
26. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes. Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135 [TBL] [Abstract][Full Text] [Related]
27. Chromosome 20q13.2 ZNF217 locus amplification correlates with decreased E-cadherin expression in ovarian clear cell carcinoma with PI3K-Akt pathway alterations. Huang HN; Huang WC; Lin CH; Chiang YC; Huang HY; Kuo KT Hum Pathol; 2014 Nov; 45(11):2318-25. PubMed ID: 25281027 [TBL] [Abstract][Full Text] [Related]
28. Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma. Caumanns JJ; Berns K; Wisman GBA; Fehrmann RSN; Tomar T; Klip H; Meersma GJ; Hijmans EM; Gennissen AMC; Duiker EW; Weening D; Itamochi H; Kluin RJC; Reyners AKL; Birrer MJ; Salvesen HB; Vergote I; van Nieuwenhuysen E; Brenton J; Braicu EI; Kupryjanczyk J; Spiewankiewicz B; Mittempergher L; Bernards R; van der Zee AGJ; de Jong S Clin Cancer Res; 2018 Aug; 24(16):3928-3940. PubMed ID: 29685880 [No Abstract] [Full Text] [Related]
29. Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes. Tan TZ; Ye J; Yee CV; Lim D; Ngoi NYL; Tan DSP; Huang RY EBioMedicine; 2019 Dec; 50():203-210. PubMed ID: 31761620 [TBL] [Abstract][Full Text] [Related]
30. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Hakimi AA; Chen YB; Wren J; Gonen M; Abdel-Wahab O; Heguy A; Liu H; Takeda S; Tickoo SK; Reuter VE; Voss MH; Motzer RJ; Coleman JA; Cheng EH; Russo P; Hsieh JJ Eur Urol; 2013 May; 63(5):848-54. PubMed ID: 23036577 [TBL] [Abstract][Full Text] [Related]
31. Characterization of Mutational Status, Spheroid Formation, and Drug Response of a New Genomically-Stable Human Ovarian Clear Cell Carcinoma Cell Line, 105C. Kolendowski B; Valdes YR; Hirte H; Itamochi H; Lee W; Carey M; Shepherd TG; DiMattia GE Cells; 2020 Nov; 9(11):. PubMed ID: 33153119 [TBL] [Abstract][Full Text] [Related]
32. Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma. Kuroda T; Ogiwara H; Sasaki M; Takahashi K; Yoshida H; Kiyokawa T; Sudo K; Tamura K; Kato T; Okamoto A; Kohno T Gynecol Oncol; 2019 Dec; 155(3):489-498. PubMed ID: 31604667 [TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical Analysis of the Tissue Factor Pathway Inhibitor-2 in Endometrial Clear Cell Carcinoma: A Single-center Retrospective Study. Kawaguchi R; Maehana T; Sugimoto S; Kawahara N; Iwai K; Yamada Y; Kimura F Int J Gynecol Pathol; 2024 Jan; 43(1):25-32. PubMed ID: 37255450 [TBL] [Abstract][Full Text] [Related]
34. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC. Ibragimova I; Maradeo ME; Dulaimi E; Cairns P Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518 [TBL] [Abstract][Full Text] [Related]
36. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma. Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076 [TBL] [Abstract][Full Text] [Related]
37. LncRNA GAS5 inhibits the proliferation and invasion of ovarian clear cell carcinoma via the miR-31-5p/ARID1A axis. Zhang J; Yang ZM; Huang Y; Wang KN; Xie Y; Yang N Kaohsiung J Med Sci; 2021 Nov; 37(11):940-950. PubMed ID: 34414664 [TBL] [Abstract][Full Text] [Related]
38. Distinguishing the progression of an endometrioma: Benign or malignant? Bastu E; Onder S; Demiral I; Ozsurmeli M; Keskin G; Takmaz O; Ozaltin S; Gorgen H; Gungor M; Yavuz E; Buyru F Eur J Obstet Gynecol Reprod Biol; 2018 Nov; 230():79-84. PubMed ID: 30245441 [TBL] [Abstract][Full Text] [Related]
39. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Jones S; Wang TL; Shih IeM; Mao TL; Nakayama K; Roden R; Glas R; Slamon D; Diaz LA; Vogelstein B; Kinzler KW; Velculescu VE; Papadopoulos N Science; 2010 Oct; 330(6001):228-31. PubMed ID: 20826764 [TBL] [Abstract][Full Text] [Related]
40. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]